ACUTE LEUKEMIA

OBJECTIVE

- Define acute leukemia
- Classify leukemia
- Understand the pathogenesis
- Understand the pathophysiology
- Able to list down the laboratory investigations required for diagnosis
- Understand the basic management of leukemia patients

Acute Leukemia

- Define : heterogenous group of malignant disorders which is characterized by uncontrolled clonal and accumulation of blasts cells in the bone marrow and body tissues
- Sudden onset
- If left untreated is fatal within a few weeks or months
- **Incidence 1.8/100,000**

Acute Leukemia

- ***Classification :***
  - **Acute**
    - Acute lymphoblastic leukemia (T-ALL & B-ALL)
    - Acute myeloid leukemia
  - **Chronic**
    - Chronic myeloid leukemia
    - Chronic lymphocytic leukemia

FAB Acute Myeloid Leukemia

Acute nonlymphocytic (ANLL) **% Adult cases**


M0 Minimally differentiated AML 5% - 10%
Negative or < 3% blasts stain for MPO ,PAS and NSE

blasts are negative for B and T lymphoid antigens, platelet glycoproteins and erythroid glycophorin A.

Myeloid antigens : CD13, CD33 and CD11b are positive.

M1 Myeloblastic without maturat
20%

- >90% cells are myeloblasts
- 3% of blasts stain for MPO
- +8 frequently seen




M2 AML with maturation

30 - 40%

30% - 90% are myeloblasts

~ 15% with t(8:21)



M3 Acute Promyelocytic Leukemia (APML) 10-15%

marrow cells hypergranular promeyelocytes


Auer rods/ faggot cells may be seen


Classical-Hypergranular, 80% leukopaenic

Variant-Hypogranular, leukocytosis

Granules contain procoagulants (thromboplastin-like) - massive DIC

t(15:17) is diagnostic






M4 Acute Myelomonocytic Leukemia 10-15%


Incresed incidence CNS involvement

Monocytes and promonocytes 20% - 80%

M4 with eosinophilia ((M4-Eo), assoc with del/inv 16q

– marrow eosinophil from 6% - 35%,






M5a Acute Monoblastic Leukemia
10-15%


M5b AMoL with differentiation <5%

Often associated with infiltration into gums/skin

Weakness, bleeding and diffuse erythematous skin rash








M6 Erythroleukemia (Di Guglielmo) <5%

50% or more of all nucleated marrow cells are erythroid precursors,


and 30% or more of the remaining nonerythroid cells are myeloblasts (if <30% then myelodysplasia)



M7 Acute Megakaryoblastic Leukemia <5%

Assoc with fibrosis


(confirm origin with platelet peroxidase + electron microscopy or MAb to vWF or glycoproteins





FAB Acute Lymphoblastic Leukemia


Acute lymphoblastic leukemia (ALL)*

L-1	85%
L-2	14%
L-3 (Burkitt's)	1% childhood








PLURIPOTENTIAL HEMOPOIETIC STEM CELL
MULTIPOTENTIAL STEM CELLS
PROGENITOR CELLS
PRECURSOR CELLS
Lymphoid
Nonlymphoid
B
T
Megakaryocytic
Erythroid
Myeloid
Antigen-independent B cell
Antigen-independent T cell
Antigen-dependent activation and transformation
B immunoblast
T immunoblast
B memory
B plasma cell
T memory helper suppressor
Large granular lymphocyte
?
Megakaryoblast
Megakaryocyte
Platelet
Pronormoblast
Basophilic normoblast
Polychromatophilic normoblast
Orthochromatophilic normoblast
Reticulocyte
Erythrocyte
Monoblast
Promonocyte
Monocyte
Myeloblast
Promyelocyte
Myelocytes
Eosinophilic
Neutrophilic
Basophilic
Metamyelocytes
Eosinophilic
Neutrophilic
Basophilic
Bands
Eosinophilic
Neutrophilic
Basophilic
Eosinophil
Neutrophil
Basophil

Acute Leukaemogenesis

Develop as a result of a genetic alteration within single cell in the bone marrow

a*)* ***Epidemiological evidence :***

1. Hereditary Factors

- **Fanconi's anaemia**
- **Down's syndrome**
- **Ataxia telangiectasia**

Acute Leukaemogenesis

2. Radiation, Chemicals and Drugs
3. Virus related Leukemias

- Retrovirus :- HTLV 1 & EBV



Acute Leukaemogenesis

b)Molecular Evidence

- ***Oncogenes* :**
- **Gene that code for proteins involved in cell proliferation or differentiation**
- ***Tumor Suppressor Genes :***
- **Changes within oncogene or suppressor genes are necessary to cause malignant transformation.**

Acute Leukaemogenesis

Oncogene can be activated by :

- **chromosomal translocation**
- **point mutations**
- **inactivation**

- In general, several genes have to be altered to effect neoplastic transformation

Pathophysiology

- Acute leukemia cause morbidity and mortality through :-
  - **Deficiency in blood cell number and function**
  - **Invasion of vital organs**
  - **Systemic disturbances by metabolic imbalance**

Pathophysiology

A. Deficiency in blood cell number or function

i. Infection

- Most common cause of death
- Due to impairment of phagocytic function and neutropenia

Pathophysiology

ii. Hemorrhage

- Due to thrombocytopenia or 2° DIVC or liver disease

iii. Anaemia

- normochromic-normocytic
- severity of anaemia reflects severity of disease
- Due to ineffective erythropoiesis

Pathophysiology

B. Invasion of vital organs

- **vary according to subtype i.Hyperleukocytosis**
- **cause increase in blood viscosity**
- **Predispose to microthrombi or acute bleeding**
- **Organ invole : brain, lung, eyes**
- **Injudicious used of packed cell transfusion precipitate**

Pathophysiology

ii. Leucostatic tumour

- Rare
- blast cell lodge in vascular system forming macroscopic pseudotumour – erode vessel wall cause bleeding

iii. Hidden site relapse

- testes and meninges

Pathophysiology

C. Metabolic imbalance

- Due to disease or treatment
- Hyponatremia vasopressin-like subst. by myeloblast
- Hypokalemia due to lysozyme release by myeloblast
- Hyperuricaemia- spont lysis of leukemic blast release purines into plasma

Acute Lymphoblastic Leukaemia

- **Cancer of the blood affecting the white blood cell known as *LYMPHOCYTES.***
- **Commonest in the age 2-10 years**
- **Peak at 3-4 years.**
- **Incidence decreases with age, and a secondary rise after 40 years.**
- **In children - most common malignant disease**
- **85% of childhood leukaemia**

Acute Lymphoblastic Leukemia

Specific manifestation :

- ***bone pain, arthritis**
- ***lymphadenopathy**
- ***hepatosplenomegaly**
- ***mediastinal mass**
- ***testicular swelling**
- ***meningeal syndrome**

Acute Myeloid Leukemia

- Arise from the malignant transformation of a myeloid precursor
- Rare in childhood (10%-15%)
- The incidence increases with age
- 80% in adults
- Most frequent leukemia in neonate

Acute Myeloid Leukemia

Specific manifestation :

- Gum hypertrophy
- Hepatosplenomegaly
- Skins deposit
- Lymphadenopathy
- Renal damage
- **DIVC**

Investigations

1. Full blood count


- **reduced haemoglobin normochromic, normocytic anaemia,**
- **WBC**

<1.0x10⁹/l to >200x10⁹/l, neutropenia and f blast cells


- **Thrombocytopenia**
- **<10x10⁹/l),**



Investigations



Acute lymphoblastic leukemia



Acute myeloid leukemia

Investigations

- **ALL(Lymphoblast)**
  - **Blast size** :small
  - **Cytoplasm**: Scant
  - **Chromatin**: Dense
  - **Nucleoli** :Indistinct
  - **Auer-rods**: Never present
- **AML (Myeloblast)**
  - Large
  - Moderate
  - Fine, Lacy
  - Prominent
  - Present in 50%


Investigations

2. Bone marrow aspiration **and trephine biops**

- **confirm acute leukaemia**

  (blast > 30%)

- **usually hypercellular**




Investigations

3.
Cytochemical staining

α)
Peroxidase :-

- * **negative ALL**
- * **positive AML**




Positive for myeloblast

Investigations

b) Periodic acid schiff

***Positive ALL (block)**

*** Negative AML**




Block positive in ALL

Investigations

c) Acid phosphatase :

focal positive (T-ALL)




Investigations

4.Immunophenotyping

- **identify antigens present on the blast cells**
- **determine whether the leukaemia is lymphoid or myeloid(**especially important when cytochemical markers are negative or equivocal. E.g : AML-MO)
- **differentiate T-ALL and B-ALL**

- Certain antigens have prognostic significance
- Rare cases of biphenotypic where both myeloid and lymphoid antigen are expressed
- Able to identify the subtype of leukemia. E.g : AML-M7 has a specific surface marker of CD 61 etc


B Lymphocyte Differentiation
Stem cell
Pro B
Pre B
Immature B
Mature B
Activated B
Plasma cell
CD19
CD10
CD20
CD22
CD21
CD38
HLA-DR
C Ig
S Ig
#
$
†
T Lymphocyte Differentiation
Pro thymocyte
Subcapsular thymocyte
Cortical thymocyte
Medullary thymocyte
Mature T
CD7
CD2
CD5
CD3
CD1
CD4
CD8

- Monoclonal antibodies(McAb) are recognised under a cluster of differentiation(CD).

MONOCLONAL ANTIBODIES USED FOR CHARACTERISATION OF ALL AND AML.

Monoclonal antibodies

AML :		CD13, CD33
ALL :	B-ALL	CD10, CD 19, CD22
	T-ALL	CD3, CD7

Investigations

5. Cytogenetics and molecular studies

- **detect abnormalities within the leukaemic clone**
- **diagnostic or prognostic value**
- **E.g : the Philadelphia chromosome : the product of a translocation between chromosomes 9 and 22**
- **confers a very poor prognosis in ALL**

Investigations

COMMON CHROMOSOME ABNORMALITIES ASSOCIATED WITH ACUTE LEUKEMIA

- t(8;21) AML with maturation (M2)
- t(15;17) AML-M3(APML)
- Inv 16 AML-M4
- t(9;22) Chronic granulocytic leukemia
- t(8;14) B-ALL

Others Invx

6. Biochemical screening

- **leucocyte count very high - renal impairment and hyperuricaemia**

7. Chest radiography

- **mediastinal mass - present in up to 70% of patients with T -ALL**

  In childhood ALL bone lesions may also seen.

Other Investigation

8.Lumbar puncture

- **initial staging inv. to detect leukaemic cells in the cerebrospinal fluid, indicating involvement of the CNS**
- Done in acute lymphoblastic leukemia

Management

Supportive care

1. Central venous catheter inserted to :

- **facilitate blood product**
- **adm. of chemotherapy and antibiotics**
- **frequent blood sampling**

Management

2. Blood support :-

- **platelet con. for bleeding episodes or if the platelet count is <10x10⁹/l with fever**
- **fresh frozen plasma if the coagulation screen results are abnormal**
- **packed red cell for severe anaemia (caution : if white cell count is extremely high)**

Management

3. **Prevention and control infection**

- **barrier nursed**
- **Intravenous antimicrobial agents if there is fever or sign of infection**

Management

4. Physiological and social support



Specific treatment

Use of cytotoxic chemotherapy.

- Aim :
- To induce remission
- (absence of any clinical or conventional laboratory evidence of the disease)
- To eliminate the hidden leukemic cells

Cytotoxic chemotherapy

- Anti-metabolites
  - Methotrexate
  - Cytosine arabinoside
    - Act: inhibit purine & pyrimidine synthesis or incorprate into DNA
    - S/E : mouth ulcer, cerebellar toxicity
- DNA binding
  - Dounorubicin
    - Act : bind DNA and interfere with mitosis
    - S/E : Cardiac toxicity, hair loss

Cytotoxic chemotherapy

- Mitotic inhibitors
  - Vincristine
  - Vinblastine
    - Act : Spindle damage, interfere with mitosis
    - S/E : Neuropathy, Hair loss
- Others
  - Corticosteroid
    - Act : inhibition or enhance gene expression
  - Trans-retinoic acid
    - Act : induces differentiation

Complications

Early side effects

- **nausea and vomiting**
- **mucositis, hair loss, neuropathy, and renal and hepatic dysfunction**
- **myelosuppression**

Complications

Late effects

- ***Cardiac*–Arrhythmias, cardiomyopathy**
- ***Pulmonary*–Fibrosis**
- ***Endocrine*–Growth delay, hypothyroidism, gonadal dysfunction**
- ***Renal*–Reduced GFR**
- ***Psychological*–Intellectual dysfunction,**
- ***Second malignancy***

Poor Prognostic Factors

	ALL	AML
Age	<1	> 60 year
TWBC	> 50 x 10^9/l	High
CNS (rare)	present	present
Sex male/female	male	
Cytogenetic	t(9;22)	monosomy 5, 7